Among patients with a known gene alteration status, PI3K activation (defined as PIK3CA mutation, PIK3CA amplification, PTEN mutation, and PTEN loss) was exhibited in 19% (8/42) of patients with ESCC. This evidence concerns the gene PTEN and esophageal squamous cell carcinoma.